by webmaster | Aug 26, 2022 | News en
Sensidose recently reported an increase in net sales of 21 per cent for the second quarter compared to the same period in 2021. At the same time as the company is growing, they have also made progress during the quarter in the development of the new dosing device,... 
by webmaster | Mar 10, 2022 | News en
Sensidose will participate at the BioStock Investor Meeting on March 16. The presentation starts at 14:05. Follow the event online here: https://youtu.be/tv-ZDUn3zzI #Sensidose #BioStockSWE #investormeeting... 
by webmaster | Aug 19, 2019 | News en
Sensidose AB (the “Company”) has entered into a service agreement with Desitin Arzneimittel GmbH (“Desitin”) for the sales and marketing of Flexilev (under the trade name Suades) in Germany. Sensidose and Desitin will share the revenue from the... 
by webmaster | Mar 20, 2019 | News en
Sensidose receives SEK 1.22 million in grants from Vinnova for industrial research within the call “Innovation projects in companies”. The funding aims to support the company’s development of measuring physiological reactions to pain to enable... 
by webmaster | Aug 27, 2018 | News en
Sensidose participated in the Swedish-American Life Science Summit (SALSS) between the 22nd to 24th of August 2018 in Stockholm, Sweden. The summit is a by-invitation-only conference bringing together some of the most renowned Life Science executives, scientists,...